Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02298504 · ClinicalTrials.gov registry record · Phase 4
Vital Pulp Treatment in Primary Teeth
A Phase 4 study of Indirect Pulp Cap and Pulpotomy, sponsored by University of Maryland, Baltimore.
- Active
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT02298504: Active Phase 4 study of Indirect Pulp Cap and Pulpotomy, sponsored by University of Maryland, Baltimore.
NCT02298504 is a Phase 4 study of Indirect Pulp Cap and Pulpotomy that is active but no longer recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 76 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02298504, a Phase 4 study of Indirect Pulp Cap and Pulpotomy, is active but no longer recruiting, sponsored by University of Maryland, Baltimore.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
In primary teeth, decay that is near the pulp (tooth nerve)is treated with either a pulpotomy or indirect pulp treatment if the tooth is not going to be extracted A pulpotomy involves removing the top 1/2 of the pulp, placing a medication/material on the pulp, covering the remaining pulp with a cement, and the restoring the tooth. The purpose of this pilot study is to gain preliminary information regarding the success of Biodentine, MTA, and IPT in the treatment of deep decay in children's primary molars.
Primary Outcome
No signs of abscess or any swelling related to the tooth, no signs of fistula or other pathology, no signs of pathologic mobility, no post-operative pain, no pain on palpation or percussion of the tooth
Conditions Studied
Interventions
- DRUG Mineral Trioxide Aggregate
- DRUG Biodentin
- DEVICE Vitrebond
Study Locations (1)
Maryland
- University of Maryland School of Dentistry - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 4 |
What the registry record for NCT02298504 still lists
NCT02298504 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower).
The record links to 3 conditions, with Indirect Pulp Cap appearing as the primary indexed condition, and to 3 interventions - of which Mineral Trioxide Aggregate is the first listed.
NCT02298504 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02298504 about?
NCT02298504 is a clinical study titled "Vital Pulp Treatment in Primary Teeth". In primary teeth, decay that is near the pulp (tooth nerve)is treated with either a pulpotomy or indirect pulp treatment if the tooth is not going to be extracted A pulpotomy involves removing the top 1/2 of the pulp, placing a medication/material on the pulp, covering the remaining pulp with a ceme...
What is the current status of trial NCT02298504?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2018-07-01. Estimated completion is 2026-12-01.
What conditions does trial NCT02298504 study?
This clinical trial studies the following conditions: Indirect Pulp Cap, Pulpotomy, Vital Pulp Therapies.
What interventions are being tested in trial NCT02298504?
The interventions under investigation include: Mineral Trioxide Aggregate (DRUG), Biodentin (DRUG), Vitrebond (DEVICE).
Who is sponsoring clinical trial NCT02298504?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02298504 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Indirect Pulp Cap
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02298504's enrollment target sits among peer trials
76 994th of 2000 higher than 1,000 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI